Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;9(3):407-420.
doi: 10.1007/s13555-019-0312-3. Epub 2019 Jun 29.

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis

Affiliations
Review

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis

Mary Patricia Smith et al. Dermatol Ther (Heidelb). 2019 Sep.

Abstract

Introduction: Atopic dermatitis (AD) is an inflammatory skin disease with a chronic, relapsing course. Clinical features of AD vary by age, duration, and severity but can include papules, vesicles, erythema, exudate, xerosis, scaling, and lichenification. However, the most defining and universal symptom of AD is pruritus. Pruritus or itch, defined as an unpleasant urge to scratch, is problematic for many reasons, particularly its negative impact on quality of life. Despite the profoundly negative impact of pruritus on patients with AD, clinicians and researchers lack standardized and validated methods to objectively measure pruritus. The purpose of this review is to discuss emerging methods to assess pruritus in AD by describing objective patient-centered tools developed or enhanced over the last decade that can be utilized by clinicians and researchers alike.

Methods: This review is based on a literature search in Medline, Embase, and Web of Science databases. The search was performed in February 2019. The keywords were used "pruritus," "itch," "atopic dermatitis," "eczema," "measurements," "tools," "instruments," "accelerometer," "wrist actigraphy," "smartwatch," "transducer," "vibration," "brain mapping," "magnetic resonance imaging," and "positron emission tomography." Only articles written in English were included, and no restrictions were set on study type. To focus on emerging methods, prioritization was given to results from the last decade (2009-2019).

Results: The search yielded 49 results in PubMed, 134 results in Embase, and 85 results in Web of Science. Each result was independently reviewed in a standardized manner by two of the authors (M.S., K.L.), and disagreements between reviewers were resolved by consensus. Relevant findings were categorized into the following sections: video surveillance, acoustic surveillance, wrist actigraphy, smart devices, vibration transducers, and neurological imaging. Examples are provided along with descriptions of how each technology works, instances of use in research or clinical practice, and as applicable, reports of validation studies and correlation with other methods.

Conclusion: The variety of new and improved methods to evaluate pruritus in AD is welcomed by clinicians, researchers, and patients alike. Future directions include next-generation smart devices as well as exploring new territories, such as identifying biomarkers that correlate to itch and machine-learning programs to identify itch processing in the brain. As these efforts continue, it will be essential to remain patient-centered by developing techniques that minimize discomfort, respect privacy, and provide accurate data that can be used to better manage itch in AD.

Keywords: Atopic dermatitis; Diagnosis; Eczema; Itch; Pruritus.

PubMed Disclaimer

Conflict of interest statement

Mary Patricia Smith, Karen Ly, Quinn Thibodeaux, and Thulasi Weerasinghe have nothing to disclose. Jashin J. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis; a consultant for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Promius Pharma, Regeneron, Sun Pharmaceutical, and UCB, Valeant Pharmaceuticals North America LLC; and a speaker for AbbVie, Celgene, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC. Gil Yosipovitch conducted clinical trials or received honoraria for serving as a member of the Scientific Advisory Board and consultant of TREVI, Menlo, Sienna, Regeneron Sanofi, Galderma, Novartis, Pfizer, Kiniksa, AbbVie, and Eli Lilly and received research funds from Pfizer, Sun Pharma, Kiniksa, and Leo Pharma. Tina Bhutani has received research funding from the National Psoriasis Foundation and has served as a research investigator and/or consultant for Eli Lilly, Janssen, Merck, Celgene, and Regeneron. Wilson Liao is funded in part by grants from the National Institutes of Health (U01AI119125) and has served as a research investigator for Abbvie, Amgen, Janssen, Novartis, Pfizer, and Regeneron. Wilson Liao is a member of the journal’s Editorial Board.

References

    1. Strom MA, Fishbein AB, Paller AS, Silverberg JI. Association between atopic dermatitis and attention deficit hyperactivity disorder in US children and adults. Br J Dermatol. 2016;175(5):920–929. doi: 10.1111/bjd.14697. - DOI - PMC - PubMed
    1. Schmitt J, Romanos M, Schmitt NM, Meurer M, Kirch W. Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA. 2009;301(7):724–726. doi: 10.1001/jama.2009.136. - DOI - PubMed
    1. Thyssen JP, Hamann CR, Linneberg A, et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy. 2018;73(1):214–220. doi: 10.1111/all.13231. - DOI - PubMed
    1. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428–433. doi: 10.1016/j.jaci.2012.10.041. - DOI - PMC - PubMed
    1. Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128:668–671. doi: 10.1016/j.jaci.2011.05.003. - DOI - PMC - PubMed